Severe allo-immune antibody-associated peripheral and central nervous system diseases after allogeneic hematopoietic stem cell transplantation.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
19 04 2021
Historique:
received: 19 01 2021
accepted: 24 03 2021
entrez: 20 4 2021
pubmed: 21 4 2021
medline: 11 11 2021
Statut: epublish

Résumé

Allogeneic hematopoietic stem cell transplantation (alloHSCT) is a curative treatment for hematologic malignancies. Acute and chronic graft-versus-host disease (GvHD) are the major immune-mediated complications after alloHSCT. However, there is controversy whether neurologic complications after alloHSCT might represent manifestations of GvHD. We report three patients who acquired distinct, severe immune-mediated peripheral or central nervous system diseases after alloHSCT without other, concomitant GvHD manifestations. One patient had been diagnosed with B-cell chronic lymphocytic leukemia and two patients with high risk myelodysplastic syndrome. Patient #1 presented as LGI1- and GAD-IgG positive immune-mediated encephalitis, patient #2 was diagnosed with MOG-IgG positive encephalomyelitis, and patient #3 had chronic inflammatory polyneuropathy associated with SSA(Ro)-IgG positive Sjögren's syndrome. 100% donor chimerism was detectable in the peripheral blood in all three. The specific antibodies were undetectable in donors' and patients' blood before alloHSCT suggesting that the antibodies had arisen from the transplanted donor immune system. Early intensive immunotherapy led to improvement of clinical symptoms and stability of the neurological disease, however, at the cost of losing the graft-versus-malignancy effect in one patient. In conclusion, we provide evidence of isolated, severe allo-immune diseases of the peripheral and central nervous system as complications of alloHSCT ("neuro-GvHD"). Interdisciplinary surveillance and thorough diagnostic work-up are needed for early diagnosis and treatment of neuro-immunologic complications after alloHSCT to improve the otherwise poor outcome.

Identifiants

pubmed: 33875720
doi: 10.1038/s41598-021-87989-z
pii: 10.1038/s41598-021-87989-z
pmc: PMC8055885
doi:

Substances chimiques

Antibodies 0

Types de publication

Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

8527

Références

Blood. 1998 Apr 1;91(7):2619
pubmed: 9516165
Exp Hematol. 2006 May;34(5):688-94
pubmed: 16647575
Transpl Infect Dis. 2013 Dec;15(6):627-33
pubmed: 23782397
Electroencephalogr Clin Neurophysiol Suppl. 1999;52:213-20
pubmed: 10590989
Neurology. 2015 Jul 14;85(2):177-89
pubmed: 26092914
J Neuroimmunol. 2017 Jun 15;307:74-81
pubmed: 28495143
Biol Blood Marrow Transplant. 2017 Mar;23(3):388-397
pubmed: 28039081
Pediatr Neurol. 2015 Jan;52(1):119-24
pubmed: 25444090
Biol Blood Marrow Transplant. 2014 Dec;20(12):1958-67
pubmed: 25139217
Clin Chem. 2020 Nov 22;:
pubmed: 33221892
J Neuroimmunol. 2018 Oct 15;323:115-118
pubmed: 30189384
Front Immunol. 2019 May 17;10:1110
pubmed: 31164889
Biol Blood Marrow Transplant. 2015 Mar;21(3):389-401.e1
pubmed: 25529383
Hematol Oncol Stem Cell Ther. 2019 Jun;12(2):110-114
pubmed: 28549768
J Neurooncol. 2012 Nov;110(2):251-6
pubmed: 22915190
Autoimmunity. 2005 Feb;38(1):55-63
pubmed: 15804706
Ann Clin Transl Neurol. 2019 Oct;6(10):2037-2047
pubmed: 31560177
Bone Marrow Transplant. 1995 Apr;15(4):633-6
pubmed: 7655392
Neurology. 1986 Aug;36(8):1087-91
pubmed: 3526178
J Neurol. 2019 Aug;266(8):1960-1972
pubmed: 31087160
Brain Dev. 2019 Mar;41(3):301-304
pubmed: 30381136
N Engl J Med. 2017 Dec 28;377(26):2565-2579
pubmed: 29281578
Br J Haematol. 2012 May;157(3):281-90
pubmed: 22360687
Graefes Arch Clin Exp Ophthalmol. 2019 Jul;257(7):1341-1351
pubmed: 30944986
Biol Blood Marrow Transplant. 2017 Jul;23(7):1046-1053
pubmed: 28344058
Am J Clin Pathol. 1988 Apr;89(4):543-6
pubmed: 3281437
Ann Rheum Dis. 2017 Jan;76(1):9-16
pubmed: 27789466
Front Immunol. 2019 Jul 11;10:1600
pubmed: 31354737
N Engl J Med. 2018 Mar 1;378(9):840-851
pubmed: 29490181
J Neurol Neurosurg Psychiatry. 2014 Jun;85(6):638-42
pubmed: 24273223
Brain. 2010 Oct;133(10):2852-65
pubmed: 20846944
J Clin Invest. 2020 Mar 2;130(3):1315-1329
pubmed: 31846439

Auteurs

Martin W Hümmert (MW)

Department of Neurology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany. huemmert.martin@mh-hannover.de.
Department of Clinical Neuroimmunology and Neurochemistry, Hannover Medical School, Hannover, Germany. huemmert.martin@mh-hannover.de.

Michael Stadler (M)

Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany.

Lothar Hambach (L)

Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany.

Stefan Gingele (S)

Department of Neurology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany.
Department of Clinical Neuroimmunology and Neurochemistry, Hannover Medical School, Hannover, Germany.

Martin Bredt (M)

Hannover Medical School, Institute for Pathology, Hannover, Germany.

Mike P Wattjes (MP)

Department of Diagnostic and Interventional Neuroradiology, Hannover Medical School, Hannover, Germany.

Gudrun Göhring (G)

Department of Human Genetics, Hannover Medical School, Hannover, Germany.

Letizia Venturini (L)

Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany.

Nora Möhn (N)

Department of Neurology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany.
Department of Clinical Neuroimmunology and Neurochemistry, Hannover Medical School, Hannover, Germany.

Martin Stangel (M)

Department of Neurology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany.
Department of Clinical Neuroimmunology and Neurochemistry, Hannover Medical School, Hannover, Germany.

Corinna Trebst (C)

Department of Neurology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany.
Department of Clinical Neuroimmunology and Neurochemistry, Hannover Medical School, Hannover, Germany.

Arnold Ganser (A)

Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany.

Florian Wegner (F)

Department of Neurology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany.
Department of Clinical Neuroimmunology and Neurochemistry, Hannover Medical School, Hannover, Germany.

Thomas Skripuletz (T)

Department of Neurology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany.
Department of Clinical Neuroimmunology and Neurochemistry, Hannover Medical School, Hannover, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH